Filing Flows › AstraZeneca (AZN) › Recalls, complaints & regulation
AstraZeneca (AZN): recalls and clinical trials
AstraZeneca (AZN) beyond its filings: 0 recalls in the last 12 months (1 in five years, 0 Class I); 543 active clinical trials.
Latest recalls
- 2025-10-22 · FDA drug · Fasenra (benralizumab) Injection, 30 mg/mL, one single-dose pre-filled syringe, Rx only, Manufactured by: AstraZeneca AB, Sweden, Distributed by: AstraZeneca Ph
AstraZeneca's latest quarter
AstraZeneca, Q3 2026: revenue $16.2B (+7% year over year), operating margin 27.1%, net earnings $3.1B, operating cash flow $5.8B. The chart follows the revenue to costs, profit and cash.
Questions
Has AstraZeneca had any recalls?
1 recall on file over five years from the FDA, CPSC and NHTSA; 0 in the last 12 months.
How many clinical trials does AstraZeneca have?
543 active studies on ClinicalTrials.gov, 193 in phase 3.
Updated Nov 9, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.